Last updated on August 2020

Controlled Trial Evaluating Avacopan in C3 Glomerulopathy


Brief description of study

The aim of this trial is to evaluate the effect of avacopan treatment on renal disease activity in patients with complement component 3 glomerulopathy (C3G). Funding Source - FDA OOPD

Detailed Study Description

C3 glomerulopathy (C3G) is characterized by evidence of alternative complement activation based on C3 deposition in the glomeruli. There are two forms of the disease: dense deposit disease (DDD) and C3 glomerulonephritis (C3GN). There is no approved treatment for patients with C3G.

This is a randomized, double blind, placebo controlled Phase 2 study to evaluate the safety and efficacy of avacopan (CCX168) in patients with C3G. Patients receive avacopan 30mg or matching placebo orally twice-daily. The placebo-controlled treatment period is 26 weeks (182 days). This will be followed by 26 weeks during which time all patients will receive avacopan. Thereafter, all patients will be followed for eight weeks (56 days) without study drug treatment. The primary objective is to evaluate the efficacy of avacopan compared to placebo based on histologic changes in kidney biopsies taken at baseline and after 26 weeks of treatment. The primary endpoint will be based on the percent change from baseline in the C3G Histologic Index for disease activity.

Clinical Study Identifier: NCT03301467

Find a site near you

Start Over

Hospital of Miami

Miami, FL United States
  Connect »

Northwestern Medical Group

Chicago, IL United States
  Connect »

University of Iowa

Iowa City, IA United States
  Connect »

Mayo Clinic

Rochester, NY United States
  Connect »

St. Paul Hospital

Vancouver, BC Canada
  Connect »

Radboud UMC

Nijmegen, Netherlands
  Connect »

Royal London Hospital

London, United Kingdom
  Connect »

Freeman Hospital

Newcastle Upon Tyne, United Kingdom
  Connect »

Thomas Jefferson University

Philadelphia, PA United States
  Connect »

Clinical Site

Palo Alto, CA United States
  Connect »

Clinical Site

Miami, FL United States
  Connect »

Clinical Site

Chicago, IL United States
  Connect »

Clinical Site

Iowa City, IA United States
  Connect »

Clinical Site

Boston, MA United States
  Connect »

Clinical Site

New York, NY United States
  Connect »

Clinical Site

Rochester, NY United States
  Connect »

Clinical Site

Columbus, OH United States
  Connect »

Clinical Site

Philadelphia, PA United States
  Connect »

Clinical Site

Antwerp, Belgium
  Connect »

Clinical Site

Brussels, Belgium
  Connect »

Clinical Site

Vancouver, BC Canada
  Connect »

Clinical Site

Aalborg, Denmark
  Connect »

Clinical Site

Copenhagen, Denmark
  Connect »

Clinical Site

Boulogne-sur-Mer, France
  Connect »

Clinical Site

Grenoble, France
  Connect »

Clinical Site

Valenciennes, France
  Connect »

Clinical Site

Dresden, Germany
  Connect »

Clinical Site

Hannover, Germany
  Connect »

Clinical Site

Lübeck, Germany
  Connect »

Clinical Site

Amsterdam, Netherlands
  Connect »

Clinical Site

Leiden, Netherlands
  Connect »

Clinical Site

Nijmegen, Netherlands
  Connect »

Clinical Site

Barcelona, Spain
  Connect »

Clinical Site

London, United Kingdom
  Connect »

Clinical Site

Newcastle Upon Tyne, United Kingdom
  Connect »

Clinical Trial Site

East Providence, RI United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.